Hualin Chen
Zhanjiang, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
Correction: First-line serplulimab plus chemotherapy versus chemotherapy alone in small-cell lung cancer patients with brain metastases: a multicenter, prospective cohort study.
Journal: Frontiers in immunology
Published: June 28, 2026
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial.
Journal: JAMA
Published: June 17, 2026
Plain language summary: comparing ivonescimab plus chemotherapy with tislelizumab plus chemotherapy in people with advanced squamous non-small cell lung cancer in the HARMONi-6 study.
Journal: Future oncology (London, England)
Published: June 03, 2026
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China.
Journal: Lancet (London, England)
Published: April 23, 2026
First-line serplulimab plus chemotherapy versus chemotherapy alone in small-cell lung cancer patients with brain metastases: a multicenter, prospective cohort study.
Journal: Frontiers in immunology
Published: April 17, 2026
Efficacy and patient selection of consolidative thoracic radiotherapy following chemoimmunotherapy in ES-SCLC.
Journal: Frontiers in cell and developmental biology
Published: April 08, 2026
Plain language summary: comparing ivonescimab with pembrolizumab in people with PD-L1-positive non-small cell lung cancer in the HARMONi-2 study.
Journal: Future oncology (London, England)
Published: December 29, 2025
Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial.
Journal: The Lancet. Oncology
Published: November 05, 2025
Effectiveness, safety, and biomarker dynamics of lecanemab in Chinese Alzheimer's disease population: a multicenter real-world study.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: September 14, 2025
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial.
Journal: Lancet (London, England)
Published: July 23, 2025
Durvalumab Combined With Chemotherapy and SABR Therapy in Patients With Oligometastatic Non-small Cell Lung Cancer: A Multicenter Phase 2 Study.
Journal: International journal of radiation oncology, biology, physics
Published: February 01, 2025
Last Updated: 09/26/2026